Gout, a painful form of inflammatory arthritis, is poised to become a far more common diagnosis in the coming decades. According to projections reported by NEWMEDIAWIRE, the global prevalence of gout is expected to rise significantly over the next twenty-five years, driven by aging populations, obesity, and lifestyle factors. In the United States alone, over 9 million people have already been diagnosed with gout, while an even larger group—44 million people—have uric acid levels above the normal range, placing them at risk for developing the disease. This looming surge underscores an urgent need for treatments that are both effective and well tolerated.
Current standard-of-care options, primarily oral xanthine oxidase inhibitors, carry significant drawbacks. They can cause severe gastrointestinal issues, kidney toxicity, and cardiovascular risks, and they often trigger initial gout flare-ups that discourage patient adherence. Approximately 3% to 5% of patients cannot tolerate these drugs at all, and boxed warnings for cardiovascular risk further limit their use. For a chronic condition requiring long-term management, these limitations represent a substantial unmet medical need.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, is aiming to fill that gap with XORLO™, a proprietary formulation of oxypurinol. The company states that XORLO overcomes the historically poor oral absorption of oxypurinol by using a liposomal delivery system, enabling high bioavailability and rapid absorption. This allows for effective uric acid lowering at substantially lower total daily doses, potentially minimizing the toxic-level exposure and severe gastrointestinal side effects associated with high-dose traditional therapies. XORTX believes this differentiated profile could improve patient adherence and outcomes.
The company is making tangible progress toward regulatory submission. It recently announced the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102. This study is designed to characterize the pharmacokinetics and efficacy of XORLO and will require the production of GMP drug and clinical supply tablets representative of the intended commercial product. Contract production of pure oxypurinol, the active ingredient, has already begun using XORTX’s proprietary synthetic pathway.
In parallel, XORTX is working toward a new drug application submission to the FDA. The company has prepared a new Investigational New Drug (IND) application for submission in the fourth quarter of 2026, describing its clinical development plan. If the two-part trial is completed successfully, XORTX intends to request a pre-NDA meeting and prepare an NDA submission while engaging in pre-commercialization activities. The company is targeting an NDA submission in about one year and estimates a market opportunity of $700 million annually for XORLO.
“Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” said Allen Davidoff, Co-CEO of XORTX. “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.”
With gout prevalence on the rise and existing therapies often falling short due to tolerability issues, XORTX’s advancement of XORLO could represent a meaningful new option for millions of patients. The company’s progress toward an NDA, supported by manufacturing scale-up and a clear clinical roadmap, positions it as a notable player in the gout treatment landscape. As Davidoff noted, the upcoming IND submission is a critical milestone that brings XORTX one step closer to potentially addressing a significant unmet need.
